Replies to post #69214 on Biotech Values

[rkrw]

If MNTA signed the deal calling for anything more than a marginally lower profit share should Sanofi launch an authorized generic, that was a major gaffe. How to control what Sanofi will decide to do? If multiple generics are approved then no doubt nvs is out a lot of money and mnta deserves only a modest single digit royalty.

[DewDiligence]

>MNTA SNY – Another argument for bringing an AG [to market] is to deprive MNTA of the profits which may accelerate their ability to develop M118. That would have some appeal to me if I ran Sanofi so long as MNTA is picking up the tab on M118. <

This is at most a second- or third-order consideration, IMO. Why? Because, aside from Lovenox, SNY is at best a bit player in the anticoagulant arena.

The companies who stand the most to gain if M118 should falter are JNJ, Bayer, PFE, BMY, Boehringer Ingelheim, Daiichi Sankyo, and MDCO (if it gets the US Angiomax patent extended).